FDA Approved Replimune Melanoma Immunotherapy Tudriqev

The regulatory agency authorized the use of the oncolytic virus therapy in August 2026.

Updated on Sept. 21, 2026 in Cancer

Bold flat-color editorial illustration of a solitary glass medical vial, representing pharmaceutical innovation. — The U.S. Food and Drug Administration authorized the use of Replimune’s oncolytic virus therapy Tudriqev in August 2026 to treat melanoma through direct tumor injection. AI Illustration. Upload story photo >

Live Poll

Do you believe localized, direct-tumor cancer treatments will prove more effective than current systemic care methods?

In August 2026, the FDA approved Replimune's Tudriqev, marking the second oncolytic virus therapy sanctioned for direct tumor injection in the United States. This treatment aims to enhance immune responses while minimizing systemic toxicity.

Why it matters

Local delivery methods allow for effective immune activation at lower doses, which is crucial for targeting tumors when they are most vulnerable. This approach addresses the high mortality associated with cancer recurrence and metastasis.

The FDA approval follows the precedent set by Amgen's Imlygic, which was the first oncolytic virus therapy cleared in 2015. Analysts at BMO Capital Markets project Tudriqev could reach $1.3 billion in annual sales by 2035.

The players

Replimune

This biotechnology company specializes in developing oncolytic immunotherapies for the treatment of cancer.

Amgen

This multinational biopharmaceutical firm produces Imlygic, the first FDA-approved oncolytic virus therapy.

Ankyra Therapeutics

This medical developer focuses on platforms that retain drugs within tumors to improve therapeutic efficacy.

Johnson & Johnson

This healthcare corporation established a dedicated interventional oncology department in 2022 to advance localized treatments.

Surge Therapeutics

This organization develops intraoperative immunotherapies intended to target breast cancer cells.

The details

Oncolytic viruses like Tudriqev are injected directly into tumor lesions to target cancer cells, while intraoperative immunotherapy leverages surgery to deliver agents. Companies like Ankyra Therapeutics and Surge Therapeutics are also advancing platform technologies to keep drugs localized within the tumor environment.

2015: FDA approved Amgen's Imlygic.
2019: Hensify was marketed in Europe.
2022: Johnson & Johnson created an interventional oncology department.
August 2026: FDA approved Replimune's Tudriqev.
2035: Projected annual sales of $1.3 billion.

Cancer
Sept. 24
Vaccine Misinformation Threatened Cancer Treatment Progress
Cancer
Sept. 21
Moderna Shares Rose Following Cancer Vaccine News
Cancer
Sept. 21
FDA Conditionally Accepted Name for Lirafugratinib

The Big Picture

The authorization of Tudriqev follows the precedent set by the 2015 FDA approval of Amgen's Imlygic. This move reinforces the growing trend of intratumoral therapies becoming a standardized approach in modern oncology.

This approval provides a new treatment option for patients managing unresectable melanoma lesions through direct injection. It represents a shift toward more localized interventions that seek to reduce the side effects typically associated with systemic cancer therapies.

The takeaway

Direct tumor delivery systems represent a significant evolution in oncology by focusing on localized treatment to minimize systemic harm. Patients and providers should watch for upcoming trial results from developers focusing on intraoperative delivery to see how these methods could expand beyond melanoma.